Becton Dickinson (BD) and Netherlands-based diagnostics firm Check-Points Health have received CE-Mark for the use of BD MAX Check-Points CPO assay on the fully automated BD MAX System.
The new molecular screening test is designed to detect antibiotic-resistant carbapenemase-producing organisms (CPOs), which render carbapenems drug ineffective, limiting effective treatments.
BD MAX Check-Points CPO is said to identify the five most common carbapenemase genes within 2.5 hours, compared to standard techniques that usually require up to 24 hours.
Developed to replace an earlier version of the test from Check-Points, the new assay is claimed to provide improved workflow and additional target.
Early identification of patients colonised with the CPOs is expected to deliver the information to implement the required measures for infection control.
BD molecular diagnostics and women’s health vice-president Nikos Pavlidis said: “The launch of the BD MAX Check-Points CPO assay is another example of BD’s commitment to helping prevent and reduce the spread of healthcare-associated infections (HAIs) and support better antimicrobial stewardship.”
The fully integrated, automated BD MAX System performs nucleic acid extraction and real-time polymerase chain reaction (PCR) for up to 24 samples in less than three hours.
The system comes with open system capability to facilitate optimised workflow of laboratory-developed tests and other assays.
In addition to BD’s pathogen infections diagnostics portfolio, the BD MAX system menu includes panels for gastrointestinal, reproductive, and sexually transmitted infections.